6-甲基咪唑并[2,1-B][1,3]噻唑-5-羧肼 | 161563-79-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并噻唑类
• 中文名称: 6-甲基咪唑并[2,1-B][1,3]噻唑-5-羧肼
• 中文别名: 6-甲基嘧啶-[2,1-B][1,3]噻唑-5-碳酰肼；6-甲基咪唑并[2,1-B![1,3!噻唑-5-羧肼；6-甲基咪唑并[2,1-b]噻唑-5-碳酰肼
• 英文名称: 6-methylimidazo[2,1-b]thiazole-5-carbohydrazide
• 英文别名: 6-methylimidazo<2,1-b>thiazole-5-carbohydrazide；6-Methylimidazo[2,1-b][1,3]thiazole-5-carbohydrazide
• CAS: 161563-79-7
• 化学式: C₇H₈N₄OS
• mdl: MFCD03086213
• 分子量: 196.233
• InChiKey: LPBZKHDAKWWKDV-UHFFFAOYSA-N

物化性质

• 熔点：
  183-184°

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2934100090
• 危险类别：
  IRRITANT
• 安全说明：
  S26,S37/39

SDS

Name:	6-Methylimidazo[2 1-b][1 3]thiazole-5-carbohydrazide 97% Material Safety Data Sheet
Synonym:
CAS:	161563-79-7

Section 1 - Chemical Product MSDS Name:6-Methylimidazo[2 1-b][1 3]thiazole-5-carbohydrazide 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
161563-79-7	6-Methylimidazo[2,1-b][1,3]thiazole-5-	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 161563-79-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: characteristic odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 178 - 180 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H8N4OS
Molecular Weight: 196.23

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 161563-79-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
6-Methylimidazo[2,1-b][1,3]thiazole-5-carbohydrazide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 161563-79-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 161563-79-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 161563-79-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-甲基咪唑并[2,1-B][1,3]噻唑-5-羧肼 在 盐酸 、 肼 、 sodium nitrite 作用下， 反应 11.0h， 生成 N-(6-methylimidazo[2,1-b][1,3]thiazol-5-yl)hydrazinecarboxamide
  参考文献：
  名称：

  融合杂环：一些新型咪唑噻唑的合成

  摘要：

  研究了带有咪唑 [2, 1-b] [1,3] 噻唑环系统的醛腙或缩氨基脲与巯基链烷酸的反应。使用利福平作为标准，评价由此获得的化合物对结核分枝杆菌H37RV的抗分枝杆菌活性。由于耐多药结核病在临床实践中的兴起，结核病的治疗仍然是主要问题之一。多年来，异烟酸酰肼（异烟肼）一直被用作治疗疾病的主要药物。取代基和生物等排置换对其抗结核活性的影响仍在研究中 (1)。这促使我们合成 6-methylimidazo [2, l-£>] [1, 3] thiazole-5-carbohydrazide 2，异烟肼的结构类似物，及其迄今为止未报道的衍生物，以筛选其抗结核特性。氩气：a，QH5；b,C,;H4F(4); C,QH4C1(4); d、QH4Br(4)；e, QH4CH3 (4) ; f ,QH4OCH3(4) ; g,QH4NO2(2) 6-Methylimidazo[2,1-b][l,3]t

  DOI：

  10.1515/hc.2002.8.5.433
• 作为产物：
  描述：

  6-甲基咪唑[2,1-B]噻唑-5-羧酸乙酯 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以89%的产率得到6-甲基咪唑并[2,1-B][1,3]噻唑-5-羧肼
  参考文献：
  名称：

  咪唑并[2,1- b ]噻唑和苯并[ d ]咪唑并[2,1- b ]噻唑衍生物作为结核分枝杆菌泛酸合成酶抑制剂的设计，合成及生物学评价

  摘要：

  在本研究中，我们从较早报道的基于咪唑[1,2- a ]吡啶的结核分枝杆菌（MTB）中设计了咪唑并[2,1- b ]噻唑和苯并[ d ]咪唑并[2,1- b ]噻唑衍生物泛酸合成酶（PS）抑制剂。我们合成了30种化合物，并对其进行了MTB PS抑制研究，针对复制性和非复制性MTB的体外抗TB活性，使用分枝杆菌感染斑马鱼的体内活性以及对RAW 264.7细胞系的细胞毒性进行了评估。其中化合物2-甲基-N '-（4-苯氧基苯甲酰基）苯并[ d ]咪唑并[ 2,1- b ]噻唑-3-碳酰肼（5bc）表现为对MTB PS有活性的有效化合物，IC 50为0.53± 0.13μM，MIC为3.53μM，对营养缺乏的MTB降低2.1 log，在50μM时具有33％的细胞毒性。它还显示，斑马鱼中10.00 mg / kg的海螯虾的负载降低了1.5 log 。

  DOI：

  10.1016/j.bmc.2016.01.059

文献信息

• Transformations of methyl<i>L</i>-(-)-thiazolidine-4-carboxylate, 2-amino-2-thiazoline and 2-aminothiazole into thiazoloazines and azolothiazoles
  作者：Mateja Malešíč、Aleš Krbačič、Branko Stanovnik

  DOI：10.1002/jhet.5570340109

  日期：1997.1

  In the search for potential immunomodulators methyl L-(—)-thiazolidine-4-carboxylate (2), 2-amino-2-thiazoline (12), and 2-aminothiazole (19) were transformed into derivatives of various bicyclic systems. Thus, from compound 2 derivatives of perhydrothiazolo[3,4-a]pyrazine 4 and 5, perhydrothiazolo[4,3-c]-[1,4]oxazine 7, and perhydroimidazo[1,5-c]thiazole 9a,b, from compound 12 derivatives of 2,3-dihydro-thiazolo[2

  在寻找潜在的免疫调节剂时，将L -（-）-噻唑烷-4-羧酸甲酯（2），2-氨基-2-噻唑啉（12）和2-氨基噻唑（19）转化为各种双环系统的衍生物。因此，由过氢噻唑并[3，4- a ]吡嗪4和5的化合物2衍生物，全氢噻唑并[4，3- c ]-[1，4]恶嗪7和全氢咪唑并[1，5- c ]噻唑9a，b形成。由2,3-二氢噻唑并[2,3- b ]嘧啶13a，b的化合物12衍生物和咪唑并[2,1- b ]噻唑的化合物19衍生物制备21、22、24和25 。6-（对氨基磺酰基苯基）-7-氧杂氢咪唑[1,5- c发现]噻唑-5-硫酮（9a）具有免疫修复活性。
• Synthesis and antimycobacterial activity of new imidazo[2,1-b]thiazole derivatives
  作者：Z Cesur、H Güner、G Ötük

  DOI：10.1016/0223-5234(94)90199-6

  日期：1994.1
• Ur, Fuesun; Cesur, Nesrin; Birteksoez, Seher, Arzneimittel-Forschung/Drug Research, 2004, vol. 54, # 2, p. 125 - 129
  作者：Ur, Fuesun、Cesur, Nesrin、Birteksoez, Seher、Oetuek, Guelten

  DOI：——

  日期：——
• Design, Synthesis and Biological Assessment of N′-(2-Oxoindolin-3-ylidene)-6-methylimidazo[2,1-b]thiazole-5-carbohydrazides as Potential Anti-Proliferative Agents toward MCF-7 Breast Cancer
  作者：Najla A. Alshaye、Mohamed K. Elgohary、Mahmoud S. Elkotamy、Hatem A. Abdel-Aziz

  DOI：10.3390/ph17020216

  日期：——

  Breast cancer is a serious threat to the health and lives of women. Two novel series of N′-(2-oxoindolin-3-ylidene)-6-methylimidazo[2,1-b]thiazole-5-carbohydrazides and 1-(aryl)-3-(6-methylimidazo[2,1-b]thiazol-5-yl)ureas were designed, synthesized and investigated for their anticancer efficacy against the MCF-7 breast cell line. Three compounds of the first series showed potent activity toward MCF-7 with IC50 in the range 8.38–11.67 µM, respectively, as compared to Sorafenib (IC50 = 7.55 µM). N′-(1-butyl-2-oxoindolin-3-ylidene)-6-methylimidazo[2,1-b]thiazole-5-carbohydrazide inhibited VEGFR-2 with IC50 = 0.33 µM when compared with Sorafenib (IC50 = 0.09 µM). Furthermore, this compound was introduced to PCR assessment, where it increased Bax, caspase 8, caspase 9 and cytochrome C levels by 4.337-, 2.727-, 4.947- and 2.420-fold, respectively, while it decreased levels of Bcl-2, as the anti-apoptotic gene, by 0.359-fold when compared to the untreated control MCF-7. This compound was also arrested in the G2/M phase by 27.07%, compared with 11.31% for the control MCF-7. Furthermore, it induced early and late apoptosis in MCF-7. In addition, a molecular docking study in the VEGFR-2 active site was performed to assess the binding profile for the most active compounds. Moreover, ADME parameters of the targeted compounds were also evaluated.
• FUSED HETEROCYCLES : SYNTHESIS OF SOME NEW IMIDAZOTHIAZOLES
  作者：Nesrin Cesur、Zafer Cesur、Handan Guner、B. Ozden Kasimoğullari

  DOI：10.1515/hc.2002.8.5.433

  日期：2002.1

  Reaction of aldehyde-hydrazones or semicarbazones bearing an imidazo [2, 1-b] [1,3]thiazole ring system with mercaptoalkanoic acids were investigated. Antimycobacterial activities of compounds thus obtained were evaluated against Mycobacterium tuberculosis H37RV using rifampine as standard. Treatment of tuberculosis is still one of the major problems due to the rise of multidrug resistant tuberculosis

  研究了带有咪唑 [2, 1-b] [1,3] 噻唑环系统的醛腙或缩氨基脲与巯基链烷酸的反应。使用利福平作为标准，评价由此获得的化合物对结核分枝杆菌H37RV的抗分枝杆菌活性。由于耐多药结核病在临床实践中的兴起，结核病的治疗仍然是主要问题之一。多年来，异烟酸酰肼（异烟肼）一直被用作治疗疾病的主要药物。取代基和生物等排置换对其抗结核活性的影响仍在研究中 (1)。这促使我们合成 6-methylimidazo [2, l-£>] [1, 3] thiazole-5-carbohydrazide 2，异烟肼的结构类似物，及其迄今为止未报道的衍生物，以筛选其抗结核特性。氩气：a，QH5；b,C,;H4F(4); C,QH4C1(4); d、QH4Br(4)；e, QH4CH3 (4) ; f ,QH4OCH3(4) ; g,QH4NO2(2) 6-Methylimidazo[2,1-b][l,3]t